|
| 36710205 | Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. | Eur Urol | 2024 |
| 36526385 | In Regard to Fornacon-Wood et al. | Int J Radiat Oncol Biol Phys | 2023 |
| 35849035 | Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. | Neuro Oncol | 2023 |
| 35657335 | Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. | Neuro Oncol | 2023 |
| 36260832 | NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. | Journal of Clinical Oncology | 2023 |
| 37944590 | Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. | Nat Med | 2023 |
| 36592721 | Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2023 |
| 37343523 | Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas. | Cell Rep Med | 2023 |
| 36579470 | Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126. | Cancer | 2023 |
| 37079324 | Stereotactic Radiosurgery vs Conventional Radiotherapy for Localized Vertebral Metastases of the Spine: Phase 3 Results of NRG Oncology/RTOG 0631 Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 37393743 | Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203. | Gynecol Oncol | 2023 |
| 36993741 | Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. | Res Sq | 2023 |
| 36736921 | Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415. | Int J Radiat Oncol Biol Phys | 2023 |
| 34481017 | Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. | Int J Radiat Oncol Biol Phys | 2022 |
| 36299794 | Germline polymorphisms in <i>MGMT</i> associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825. | Neurooncol Adv | 2022 |
| 35960897 | Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial. | J Clin Oncol | 2022 |
| 36420209 | Association of Pretreatment Hippocampal Volume With Neurocognitive Function in Patients Treated With Hippocampal Avoidance Whole Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology/RTOG 0933. | Advances in Radiation Oncology | 2022 |
| 34919884 | Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. | Int J Radiat Oncol Biol Phys | 2022 |
| 35096402 | Missing repeated measures data in clinical trials. | Neuro-Oncology Practice | 2022 |
| 34882500 | Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004. | J Clin Oncol | 2022 |
| 34589661 | Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma. | JCO Precis Oncol | 2021 |
| 33640421 | Missing Data in Clinical Studies. | International Journal of Radiation Oncology Biology Physics | 2021 |
| 33852571 | Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. | PLoS One | 2021 |
| 33570548 | Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. | JAMA Oncol | 2021 |
| 33567304 | Psychological Treatment for Patients Receiving Radiation: Results of NRG Oncology/RTOG 0841. | Int J Radiat Oncol Biol Phys | 2021 |
| 33515019 | Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). | Neuro-Oncology | 2021 |
| 33608427 | Fundamental Statistical Concepts in Clinical Trials and Diagnostic Testing. | | 2021 |
| 32894431 | Do reminder emails and past due notifications improve patient completion and institutional data submission for patient-reported outcome measures? | Qual Life Res | 2021 |
| 34761331 | Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. | J Neurooncol | 2021 |
| 33427658 | Prognostic Significance of IDH1/2 Mutation and MGMT Promoter Methylation Status in RTOG 9813. | Int J Radiat Oncol Biol Phys | 2020 |
| 32073955 | Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study. | J Clin Oncol | 2020 |
| 32251755 | Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424. | International Journal of Radiation Oncology Biology Physics | 2020 |
| 32058845 | Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. | J Clin Oncol | 2020 |
| 32105798 | Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. | J Clin Epidemiol | 2020 |
| 32590048 | Characteristics of Participation in Patient-Reported Outcomes and Electronic Data Capture Components of NRG Oncology Clinical Trials. | Int J Radiat Oncol Biol Phys | 2020 |
| 31104905 | Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy. | Gynecol Oncol | 2019 |
| 31673651 | Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933. | Adv Radiat Oncol | 2019 |
| 29618054 | Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. | Neurosurgery | 2019 |
| 30926221 | An investigator's introduction to statistical considerations in clinical trials. | Urologic Oncology: Seminars and Original Investigations | 2019 |
| 31540746 | Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. | Radiother Oncol | 2019 |
| 31435980 | Changing functional status within 6 months posttreatment is prognostic of overall survival in patients with head and neck cancer: NRG Oncology Study. | Head Neck | 2019 |
| 31015166 | Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. | Radiother Oncol | 2019 |
| 31386073 | The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy. | Neurooncol Pract | 2019 |
| 27100959 | Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123. | Am J Clin Oncol | 2018 |
| 30202809 | Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities. | Adv Radiat Oncol | 2018 |
| 29913254 | Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2018 |
| 30094545 | Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. | Ann Nucl Med | 2018 |
| 29908786 | Attrition in NRG Oncology's Radiation-Based Clinical Trials. | Int J Radiat Oncol Biol Phys | 2018 |
| 29989857 | Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203. | J Clin Oncol | 2018 |
| 29413282 | First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. | Int J Radiat Oncol Biol Phys | 2018 |